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Abstract
The investigation of the (patho)physiological role of the histamine H4 receptor (H4R) and its validation as a possible drug
target in translational animal models are compromised by distinct species-dependent discrepancies regarding potencies
and receptor subtype selectivities of the pharmacological tools. Such differences were extremely pronounced in case of
proximal readouts, e. g. [32P]GTPase or [35S]GTPcS binding assays. To improve the predictability of in vitro investigations,
the aim of this study was to establish a reporter gene assay for human, murine and rat H4Rs, using bioluminescence as a
more distal readout. For this purpose a cAMP responsive element (CRE) controlled luciferase reporter gene assay was
established in HEK293T cells, stably expressing the human (h), the mouse (m) or the rat (r) H4R. The potencies and efficacies
of 23 selected ligands (agonists, inverse agonists and antagonists) were determined and compared with the results
obtained from proximal readouts. The potencies of the examined ligands at the human H4R were consistent with reported
data from [32P]GTPase or [35S]GTPcS binding assays, despite a tendency toward increased intrinsic efficacies of partial
agonists. The differences in potencies of individual agonists at the three H4R orthologs were generally less pronounced
compared to more proximal readouts. In conclusion, the established reporter gene assay is highly sensitive and reliable.
Regarding discrepancies compared to data from functional assays such as [32P]GTPase and [35S]GTPcS binding, the readout
may reflect multifactorial causes downstream from G-protein activation, e.g. activation/amplification of or cross-talk
between different signaling pathways.
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Introduction
The histamine H4 receptor (H4R) [1–5] is preferably expressed
on cells of hematopoietic origin such as eosinophils and mast cells
and supposed to be involved in inflammatory diseases, e.g. asthma,
and pruritis [6–10]. To investigate the (patho)physiological role of
the H4R translational, animal models for allergic asthma and
allergic contact dermatitis in mice [11–15] or rat models for acute
inflammation and conjunctivitis [16,17] were used. Most of the
studies confirmed the pro-inflammatory role of the H4R by
blocking the H4R-mediated response with JNJ 7777120 (1-[(5-
chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine), which is re-
ported to be equipotent as an antagonist at the human, mouse and
rat H4R orthologs [18].
However, there are also controversial reports. The administra-
tion of the H4R agonist 5(4)-methylhistamine was benefical in a
murine asthma model [12], and JNJ 7777120 increased the ocular
histamine concentration in a rat conjunctivitis model [17] (for a
recent review cf. Neumann et al. [19]). Furthermore, the overall
amino acid identities of H4R species orthologs are remarkably low
(human versus mouse and rat: ,70%) compared to other
histamine receptor subtypes (H1R, H2R and H3R) [20]. Although
relatively small differences in the sequence of histamine receptor
species orthologs can result in different potencies and efficacies of
individual ligands, the discrepancies are exceptionally high in case
of the H4R [21]. In various in vitro assay systems the
recombinantly expressed mouse and rat H4R revealed substantial
species-dependent differences compared to the human receptor
concerning affinity, potency and quality of action of pharmaco-
logical tools, compromising the predictive value with respect to
translational animal models [20–23]. For example, in comparison
to the human H4R, UR-PI294 (N
1-[3-(1H-imidazol-4-yl)propyl]-
N2-propionylguanidine) and UR-PI376 (2-cyano-1-[4-(1H-imida-
zol-4-yl)butyl]-3-[(2-phenylthio)ethyl]guanidine) [24,25] displayed
considerably lower potencies and efficacies (UR-PI376) in the
[32P]GTPase and [35S]GTPcS binding assays on membrane
preparations of Sf9 insect cells expressing the mouse or rat H4R
[23]. Most strikingly, JNJ 7777120 exhibited stimulatory effects at
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the mouse and rat H4R in functional assays on Sf9 cell membranes
[23]. Moreover, the use of JNJ 7777120 as standard antagonist in
animal models was questioned due to stimulation of G-protein
independent b-arrestin recruitment [26]. Biased signaling of the
hH4R has also been shown for other H4R ligands [27].
The aforementioned controversial findings underline the
necessity to evaluate pharmacological tools at the H4R species
orthologs of interest using different assay systems. For this purpose,
a cAMP response element (CRE) controlled luciferase reporter
gene assay in HEK293T cells, stably expressing the human, the
mouse or the rat H4R, was established. The H4R is Gai/o-coupled
and reduces forskolin stimulated cyclic adenosine monophosphate
(cAMP) formation after agonist binding [2]. The optimal
concentration of forskolin used for pre-stimulation depends on
the cell type [28] and should correspond to the EC50 of forskolin in
the assay system [29]. Therefore, the potency of forskolin was
determined, and the effect of the phosphodiesterase (PDE)
inhibitor isobutylmethylxanthine (IBMX) was evaluated to opti-
mize the sensitivity of the procedure. Due to the delayed onset of
gene expression, incubation periods of four to six hours are
required [30], increasing the risk of agonist mediated receptor
desensitization, which can lead to a decrease in agonist potencies
[30]. Therefore, the time course of the luciferase expression was
determined to find the minimum incubation period required for
appropriate signal strength. For validation, potencies and efficacies
of 23 selected H4R ligands, comprising agonists, inverse agonists
and antagonists, were determined (Figure 1).
Materials and Methods
Ethics Statement
Human embryonal kidney (HEK293T) cells were purchased
from the German Collection of Microorganism and Cell Cultures
(DSMZ, Braunschweig, Germany).
Histamine Receptor Ligands
Histamine (HA, 1) was purchased from Alfa Aesar (Karlsruhe,
Germany). (R)-a-methylhistamine (2), (S)-a-methylhistamine (3),
Na-methylhistamine (4), 5(4)-methylhistamine (5), immepip (6),
immethridine (7), imetit (8), clobenpropit (9), iodophenpropit (10),
proxyfan (PRO, 11), ciproxifan (CIP, 12), clozapine (17), VUF
5681 (18), A 943931 (22) and A 987306 (23) were from Tocris
Bioscience (Ellisville, MO, USA), UR-PI294 (13), UR-PI376 (14),
VUF 8430 (15), ST-1006 (16), JNJ 7777120 (19), thioperamide
Figure 1. Chemical structures of the examined H4R ligands. Agonists (1–17), antagonists/inverse agonists (18–23) at the human H4R.
doi:10.1371/journal.pone.0073961.g001
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(THIO, 20), and ST-1012 (21) were synthesized in our
laboratories. Chemical structures of the ligands are depicted in
Figure 1. Except for 14, 16, 17, 21 and 23 all stock solutions
(10 mM) were prepared in Millipore water. Stock solution of 17
and 23 were made in 20 mM HCl, whereas 14, 16 and 21 were
dissolved in 50% (v/v) dimethyl sulfoxide (DMSO). Stock solutions
of 17 and 23 and those ligands dissolved in water were diluted
with Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% (v/v) fetal calf serum (FCS). The stock solutions of 14,
16 and 21 were diluted with DMEM supplemented with 10% (v/
v) FCS and 10% (v/v) DMSO.
Subcloning of FLAG Epitope- and Hexahistidine-tagged
mH4R cDNA into the Shuttle Vector pcDNA3.1(+)
The FLAG epitope (F)- and the hexahistidine (His6)-tagged
mH4R cDNA cloned in pGEM-3Z [23] was subcloned at HindIII
and XbaI restriction sites into pcDNA3.1(+), encoding G418
resistance. Double digestion with HindIII (Fermentas GmbH, St.
Leon-Rot, Germany) and XbaI (Fermentas) restriction enzymes
was performed in reaction buffer Tango (Fermentas) with a two-
fold excess of HindIII at 37uC for 3 h. The DNA bands of the SF-
mH4R-His6 (1336 bp) (S stands for the cleavable signal peptide
from influenza hemagglutinin, F for flag) insert as well as the
linearized pcDNA3.1(+) vector (5352 bp) were extracted from the
Figure 2. Stimulation of luciferase activity by forskolin. (A)
Representative time course of the luciferase expression in HEK293T-
CRE-Luc cells, stably expressing the CRE-controlled luciferase, upon
stimulation with 10 mM of forskolin. The luciferase activity was
determined after the indicated incubation periods (mean values 6
SEM; n = 9). (B) Representative ‘‘bell-shaped’’ concentration-response
curve obtained with HEK293T-SF-hH4R-His6-CRE-Luc cells, stably ex-
pressing the hH4R and the CRE-controlled luciferase. (C) Concentration
response curves covering the ascending region of the signal obtained
with different transfectants.
doi:10.1371/journal.pone.0073961.g002
Figure 3. Inhibition of luciferase activity by histamine in rH4R
expressing cells. Gai/o mediated inhibition of forskolin (0.5 mM–
5.0 mM) stimulated luciferase activities by histamine (HA) in HEK293T-
SF-rH4R-His6-CRE-Luc cells, stably expressing the rH4R and the CRE-
controlled luciferase. (A) Representative luciferase reporter gene with
RLU values as readout. (B) Normalized inhibition of forskolin stimulated
luciferase activity (100%) by histamine (HA), with the maximum
inhibitory effect of which set at 0%. Data points shown are the mean
6 SEM of at least three independent experiments performed in
triplicate.
doi:10.1371/journal.pone.0073961.g003
H4R Luciferase Assay: Distal vs. Proximal Readout
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e73961
1% (m/v) agarose (pegGOLD Universal-Agarose, Peqlab, Erlan-
gen, Germany) gel using the QIAquick Gel Extraction Kit
(QIAGEN, Hilden, Germany) according to the manufacturer’s
protocol. The ligation was performed using T4-DNA-Ligase (6
Weiss U/mL) (New England Biolabs, Ipswich, MA, USA). After
the transformation of the ligation product (pcDNA3.1(+)SF-
mH4R-His6) into competent E. coli (Top10 strain) cells and plating
on agar (Roth, Karlsruhe, Germany) plates containing 100 mg/
mL of ampicillin (Sigma, Munich, Germany), one resistant colony
was chosen for large scale plasmid DNA preparation using the
Qiagen Plasmid Purification kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. The restriction
analysis with HindIII and XbaI as well as the sequencing of the
amplified pcDNA3.1(+)SF-mH4R-His6 vector (performed by
Entelechon, Bad Abbach, Germany) confirmed the correct
composition of the vector.
Cell Culture and Transfection
HEK293T cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Sigma) containing L-glutamine, 4500 mg/L
glucose, 3.7 g/L NaHCO3 (Merck, Darmstadt, Germany),
110 mg/L sodium pyruvate (Serva, Heidelberg, Germany) and
10% (v/v) fetal calf serum (FCS) (Biochrom, Berlin, Germany).
The HEK293T cells, stably expressing the tagged human H4
receptor (HEK293T-SF-hH4R-His6), were cultured in the above-
mentioned medium supplemented with 600 mg/mL geneticin
(G418) (Biochrom). Cells were maintained at 37uC and 5% CO2
in a water-saturated atmosphere in 75-cm2 culture flasks (Sarstedt,
Nu¨mbrecht, Germany) and diluted (1:10) twice a week with fresh
medium.
Figure 4. Effect of histamine and thioperamide on the
luciferase activity in hH4R expressing cells. Concentration-
response curves of histamine (HA) and thioperamide (THIO) on
HEK293T-SF-hH4R-His6-CRE-Luc cells, stably co-expressing the CRE-
controlled luciferase and the hH4R. The cells were pre-stimulated with
500 nM of forskolin alone or in combination with IBMX (50 mM). The
effect of forskolin or that of forskolin plus IBMX was defined as 100%
luciferase activity. Data points shown are the mean 6 SEM of two
independent experiments performed in triplicate.
doi:10.1371/journal.pone.0073961.g004
Table 1. Potencies and efficacies of H4R ligands in the luciferase reporter gene assay at the hH4R, the mH4R and the rH4R.
hH4R mH4R rH4R
Ligand pEC50 or (pKB) a N pEC50 or (pKB) a N pEC50 or (pKB) a N
Histamine (1) 7.7760.12 1.00 6 7.0660.13 1.00 4 6.5360.04 1.00 6
(R)-a-Methylhistamine (2) 6.4760.09 1.0360.04 5 6.1660.07 0.9860.01 6 5.6060.12 0.9660.02 3
(S)-a-Methylhistamine (3) 5.2260.09 0.9060.04 5 4.7260.16 0.8260.07 3 4.2660.04 0.6960.03 3
Na-Methylhistamine (4) 6.7460.12 0.9860.03 4 6.2460.13 0.9760.02 3 6.2360.09 0.9860.04 3
5(4)-Methylhistamine (5) 7.2560.05 0.9760.03 3 6.8760.05 0.9760.02 4 6.0360.05 1.0060.03 3
Immepip (6) 7.6460.12 0.9860.02 5 6.8560.17 0.9560.03 3 7.1760.06 0.9360.05 3
Immethridine (7) 6.1260.20 0.6560.02 3 5.9560.03 0.8760.02 3 5.8060.13 0.9460.01 3
Imetit (8) 7.5460.12 0.9460.02 5 7.4160.11 0.9660.02 3 7.2160.12 0.9560.01 4
Clobenpropit (9) 7.8760.07 0.9760.03 3 6.7360.08 0.5560.05 3 6.8060.11 0.3760.03 3
Iodophenpropit (10) 7.3060.14 0.7360.02 4 (6.6660.03) 0.0160.05 3 (6.4960.11) 20.0160.06 3
Proxyfan (11) 6.9360.06 0.6860.02 4 6.1060.07 0.8860.04 3 5.6760.13 0.7660.03 3
UR-PI294 (13) 8.7460.11 0.9860.02 6 8.2960.18 0.9760.02 5 8.1660.03 1.0360.02 3
UR-PI376 (14) 7.7060.07 1.0260.02 4 6.6160.25 0.5160.05 3 (5.1560.05) 0.0860.10 3
VUF 8430 (15) 7.0460.10 0.9760.04 3 6.8360.03 0.9660.02 3 6.0660.06 0.9860.02 3
ST-1006 (16) 8.0560.05 0.9160.01 3 7.7660.11 0.3760.04 4 6.0860.17 20.5560.12 3
Clozapine (17) 6.9660.14 1.3060.05 8 5.4460.06 0.9960.01 3 5.7060.11 1.1260.05 4
VUF 5681 (18) (6.1660.20 0.0960.00 3 5.2060.15 0.4260.02 3 n.d. – –
JNJ 7777120 (19) (7.8160.19) 20.3160.06 3 (7.5860.13) 20.2360.03 4 8.2160.10 0.4960.05 5
Thioperamide (20) 6.9260.10 20.3260.04 6 6.5260.13 20.4460.02 4 (6.8960.14) 20.2060.02 4
ST-1012 (21) 7.2660.05 20.3960.03 3 7.4960.09 0.2460.05 4 8.1260.08 0.2460.07 4
A 943931 (22) 7.5860.12 20.6360.07 6 n.d. – – (6.7960.11) 20.0660.00 6
A 987306 (23) 7.1760.07 20.6260.07 4 n.d. – – (7.8560.13) 20.0860.00 6
Data are represented as mean values6 SEM of N independent experiments performed in triplicate. a: intrinsic activity, referred to histamine = 1.00; n.d.: not determined.
doi:10.1371/journal.pone.0073961.t001
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HEK293T-SF-hH4R-His6 cells were stably co-transfected with
pGL4.29[luc2P/CRE/Hygro] (Promega, Mannheim, Germany)
encoding hygromycin resistance (Hygro) and the firefly luciferase
(luc2P), the transcription of which is controlled by the cAMP
responsive element (HEK293T-SF-hH4R-His6-CRE-Luc cells).
HEK293T cells were stably co-transfected with pGL4.29[luc2P/
CRE/Hygro] (HEK293T-CRE-Luc cells) and pcDNA3.1(+)SF-
mH4R-His6 (HEK293T-SF-mH4R-His6-CRE-Luc) or
pcDNA3.1(+)-SF-rH4R-His6 (HEK293T-SF-rH4R-His6-CRE-
Luc cells), respectively. For transfection, the cells were seeded
into a 24 well-plate (Becton Dickinson, Heidelberg, Germany), so
that they reached 60–70% confluenccy on the next day. The
transfection mixture containing 0.5 mg of the DNA and either
1 mL (4:2 ratio), 1.5 mL (6:2 ratio) or 2 mL (8:2 ratio) of
FuGeneHHD transfection reagent (Roche Diagnostics, Man-
nheim, Germany) was prepared according to the manufacturer’s
protocol and added to the cells, followed by an incubation period
of 36–48 h at 37uC and 5% CO2 in a water-saturated atmosphere.
Co-transfected cells were cultured in DMEM supplemented with
10% (v/v) FCS, 600 mg/mL of G418 and 200 mg/mL of
hygromycin B (A.G. Scientific, San Diego, USA).
Luciferase Reporter Gene Assay
Approximately 2 ? 105 transfected cells, suspended in DMEM
supplemented with 10% (v/v) FCS, were seeded per well into flat-
bottomed 96-well plates (Greiner, Frickenhausen, Germany). The
cells were allowed to attach for 17 h at 37uC, 5% CO2 in a water-
saturated atmosphere. A stock solution (10 mM) of forskolin
(Sigma) in DMSO was used to prepare feed solutions in DMEM
containing 10% (v/v) FCS (final DMSO concentration in the assay
was #1%). For experiments in the presence of a PDE inhibitor,
the feed solution of forskolin contained 500 mM of IBMX (Sigma).
After addition of forskolin (0.4 mM for the cells expressing the
human H4R and 1 mM for the rat and mouse H4R expressing
cells) alone (to determine forskolin potency) or in combination with
histaminergic ligands, the cells were incubated for 5 h. In
antagonist mode, the forskolin solution was supplemented with
0.10, 0.15 or 1.00 mM of histamine as the agonist for the human,
mouse and rat H4R expressing cells, respectively. Thereafter, the
medium was discarded, the cells were washed once with 100 mL of
phosphate buffered saline (PBS, pH 7.4) (KCl 2.7 mM; KH2PO4
1.5 mM; NaCl 137 mM; Na2HPO4 5.6 mM; NaH2PO4 1.1 mM
in Millipore water; all chemicals were from Merck, Darmstadt,
Table 2. Reference data of H4R ligands determined in the [
35S]GTPcS binding assay at the hH4R, the mH4R and the rH4R and
reported in literature.
hH4R mH4R rH4R
Ligand pEC50 or (pKB) a pEC50 or (pKB) a pEC50 or (pKB) a
Histamine (1) 7.1–8.2a,e,j,l,m 1.0 5.2–7.5a,d,e,f, l 1.0 4.3–7.1a,d,e,f,l 1.0
(R)-a-Methylhistamine (2) 6.2–7.0e,j 0.8–1.0 6.6e 0.8 6.0e 0.4
(S)-a-Methylhistamine (3) 4.9j 1.0 – – –– –
Na-Methylhistamine (4) 6.1–7.4e,j 0.9–1.0 – – – –
5(4)-Methylhistamine (5) 7.2–7.8d,j,m 0.9–1.0 6.02d 1.0 5.1d 1.1
Immepip (6) 7.7–7.8a,j 0.8–0.9 5.27a 0.7 5.0a 0.7
Immethridine (7) 6.0j 0.5 – – – –
Imetit (8) 7.9–8.5e,j 0.3–0.9 8.1e 0.8 8.1e 0.3
Clobenpropit (9) 7.7–8.3a,j,m 0.5–1.3 6.1a 0.2 (6.3)a 0.0
Iodophenpropit (10) (7.7–8.0)a,j 0.0 (6.4)a 0.0 (6.0)a 0.0
Proxyfan (11) 7.2j 0.5 – – – –
UR-PI294 (13) 8.4–8.5a,d 0.9–1.0 6.1–6.5a,d 1.0 4.6–5.5a,d 1.0–1.6
UR-PI376 (14) 7.5–7.8a,d,m 0.9–1.3 (6.1)a–6.9d 0.0–0.2 (5.5)a–4.5d 0.0–0.4
VUF 8430 (15) 7.3–8.2a,k,m 0.8–1.0 5.1a 0.7 4.5a 0.4
ST-1006 (16) 8.9c 0.2 – – – –
Clozapine (17) 5.8–6.8a,b,j,m 0.7–1.2 ,4a 0.0 ,4a 0.0
VUF 5681 (18) ,5i – – – – –
JNJ 7777120 (19) (7.6)a–7.5d 20.4d 6.1–6.7a,d 0.4–0.6 6.1–6.5a,d 0.2–0.5
Thioperamide (20) 6.4–7.0a,d,j,m –1.0 – 21.4a,d (7.1)a 0.0 (6.4)a 0.0
ST-1012 (21) 7.4c 21.1 – – – –
A 943931 (22) (8.2)g–7.3a 21.8a (8.2)g 0.0 (6.2–8.0)a,g 0.0
A 987306 (23) (8.3)h–7.1a 21.5a (8.2)h 0.0 (7.1–8.3)a,h 0.0
Reference data are taken from (unless otherwise noted, a values referred to histamine = 1.0):
afunctional [35S]GTPcS-binding assay on Sf9 cell membranes co-expressing the hH4R, mH4R or rH4R+Gia2+ b1c2;
b,c,dSteady-state [32P]GTPase assay on Sf9 cell membranes co-expressing: hH4R-RGS19+ Gia2+ b1c2 b [43], hH4R-GAIP+Gia2+ b1c2, rH4R or mH4R+Gia2+ b1c2+ GAIP d [23],
hH4R+Gia2+ b1c2 c (a value of ST-1012 referred to thioperamide =21.0, [39]);
ecalcium mobilization assay in 293-EBNA cells transiently co- expressing the hH4R, mH4R or rH4R with Gqi5 [20];
f,g,hcalcium mobilization assay in HEK293 cells stably co-expressing the hH4R, mH4R or rH4R with Gqi5
f [46], g [44], h [45];
i,j,k,lCRE-b-galactosidase reporter gene assay in SK-N-MC cells stably co-expressing: the hH4R [40–42] or the mH4R
k [57] with the CRE-b-galactosidase reporter gene;
mCRE-luciferase reporter gene assay in HEK293T cells, transiently co-expressing the hH4R with the CRE-controlled luciferase reporter gene [27];
lSRE-luciferase reporter gene assay in HEK293 cells, co-expressing the human, mouse or rat H4R+SRE-luciferase+Gaqi chimeric G-protein [57].
doi:10.1371/journal.pone.0073961.t002
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Germany) and lysed in 40 mL of lysis buffer (pH 7.8) (N-[2-
hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine (Tricine) 25 mM
(Sigma); glycerol 10% (v/v) (Merck); ethyleneglycoltetraacetic acid
(EGTA) 2 mM (Sigma); TritonTM X-100 1% (v/v) (Serva);
MgSO4 ? 7H2O, 5 mM (Merck); dithiotreitol (DTT) 1 mM
(Sigma)) for 45–60 min under shaking (180 rpm). For lumines-
cence measurement, 20 mL of lysate were transferred into a white
flat-bottomed 96-well plate (Greiner) and the GENios Pro
microplate reader (Tecan, Salzburg, Austria) was primed with
the luciferase assay buffer (pH 7.8) (glycyl-glycine (Gly-Gly)
25 mM; MgSO4 ? 7H2O, 15 mM; KH2PO4, 15 mM (Merck);
EGTA, 4 mM; adenosine 59-triphosphate (ATP) disodium salt,
2 mM (Sigma); DTT 2 mM; D-luciferin potassium salt 0.2 mg/
mL (Synchem, Felsberg, Germany)) [31]. Light emission was
induced by the injection of 80 mL of the luciferase assay buffer into
each well. Luminescence, expressed as RLUs (relative light units),
was measured for 10 s. The basal luciferase activity was subtracted
from each signal. EC50 and IC50 values were analyzed by
nonlinear regression and best fitted to sigmoidal concentration-
response curves with GraphPad Prism 5.04 (Graph Pad, San
Diego (CA), USA). IC50 values were converted to KB values using
the Cheng-Prussoff equation [32]. The intrinsic activity of ligands
Figure 5. Effect of selected standard ligands on H4R orthologs. (A) Potencies and efficacies of histamine (HA), thioperamide (THIO), UR-PI294
and JNJ 7777120 at the hH4R, (B) the mH4R and (C) the rH4R (agonist mode). (D) Reversal of the HA (100–150 nM) mediated inhibition of the forskolin-
stimulated luciferase activity by JNJ 7777120 at the hH4R and the mH4R (antagonist mode), in the luciferase reporter gene assay in HEK293T cells.
Reaction mixtures contained ligands at the concentrations indicated on the abscissa to achieve saturated concentration response curves. Data points
shown are the mean 6 SEM of at least three independent experiments performed in triplicate. Data points connected by dashed lines reflect H4R-
independent increase in luciferase activity at high ligand concentrations. The corresponding values were therefore excluded from non-linear
correlations (D).
doi:10.1371/journal.pone.0073961.g005
Figure 6. H4R-independent cellular effects of selected ligand.
Representative H4R-independent increase in the forskolin (1 mM)
stimulated luciferase activity by ciproxyfan (CIP), proxyfan (PRO), JNJ
7777120 and thioperamide (THIO) in HEK293T-CRE-Luc cells, stably
expressing the CRE-controlled luciferase and devoid of the H4R.
doi:10.1371/journal.pone.0073961.g006
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was referred to the maximal response to histamine (HA), defined
as a=1 (full agonist). Agonist potencies are given as pEC50 values
and antagonist activities were calculated as pKB values. Measured
RLUs were converted to percentual values referred to the span
between the maximum effect induced by forskolin and the residual
luciferase activity in the presence of histamine at the highest tested
concentration. All data are means 6 SEM of N independent
experiments, each performed in triplicate. For monitoring the time
course of the luciferase expression, transcription was stimulated
with 10 mM of forskolin, and the cells were lysed after various
incubation periods. For analysis, the respective basal RLUs were
subtracted from each value and plotted against the time. For
Schild analysis, concentration ratios (r) were obtained by dividing
the EC50 concentrations of agonist in the presence of JNJ 7777120
(antagonist) by the EC50 concentration of agonist in the absence of
JNJ 777120. The log (r - 1) values were plotted against the
corresponding log [JNJ 7777120] values according to the Schild
equation [33] and analyzed by linear regression with GraphPad
Prism 5.04. The pA2 values were obtained from the intercept of
the Schild plot with the x-axis.
Figure 7. Inhibition of the response to histamine and clozapine by JNJ7777120. Concentration response curves of histamine (A) and
clozapine (B) alone and in the presence of JNJ7777120 at increasing concentrations, determined on hH4R expressing HEK293T-CRE-Luc cells in the
luciferase reporter gene assay, and corresponding Schild plots (C). The pA2 values determined for JNJ 7777120 from Schild regression were 8.39
(slope: 0.8360.02) and 8.17 (slope: 0.4560.01) versus histamine and clozapine, respectively. Data points shown are the mean 6 SEM of at least three
(histamine) or five (clozapine) independent experiments performed in triplicate.
doi:10.1371/journal.pone.0073961.g007
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[35S]GTPcS Binding Assay
Cell culture and generation of high-titer recombinant baculo-
virus stocks as well as the co-infection of Sf9 cells with high-titer
baculovirus stocks encoding Gai2, Gb1c2 and the respective H4R
were performed as described recently [34,35]. Membrane
preparations were performed according to Gether et al. (1995)
[36] in the presence of 0.2 mM phenylmethylsulfonyl fluoride,
1 mM ethylenediaminetetraacetic acid (EDTA), 10 mg/mL leu-
peptin and 10 mg/mL benzamidine as protease inhibitors.
Prepared membranes were resuspended in binding buffer
(75 mM Tris/HCl, 12.5 mM MgCl2,1 mM EDTA, pH 7.4) and
stored at 280uC in 0.5 or 1.0 mL aliquots.
Membranes were thawed, centrifuged for 10 min at 4uC and
13,000 g and carefully resuspended in binding buffer. Experiments
were performed in 96-well plates in a total volume of 100 mL per
well. Each tube contained 8–12 mg of protein, 1 mM GDP,
100 mM NaCl, 0.05% (w/v) bovine serum albumine (BSA), 20
nCi of [35S]GTPcS ($0.2 nM) and ligand at various concentra-
tions. Neutral antagonists were incubated in the presence of
histamine at concentrations corresponding to the 10-fold of the
EC50 value at the respective receptor. Nonspecific binding was
determined in the presence of 10 mM unlabeled GTPcS. After
incubation under shaking at 200 rpm at room temperature for
2 h, bound [35S]GTPcS was separated from free [35S]GTPcS by
filtration through glass microfibre filters using a 96-well Brandel
harvester (Brandel Inc., Unterfo¨hring, Germany). The filters were
washed three to four times with cold binding buffer (4uC), dried
over night and impregnated with meltable scintillation wax prior
to counting with a Micro Beta2 1450 scintillation counter (Perkin
Elmer, Rodgau, Germany).
Ligands were tested in triplicate. The maximal response to
histamine was set to 100% and all other ligands were referenced to
histamine.
Results
Optimization of the Assay Conditions
In order to detect a Gai-mediated inhibitory effect on the
adenylyl cyclase (AC) activity, the reporter gene assay was
performed in the presence of the AC stimulator forskolin. The
time course of the luciferase expression upon stimulation with
10 mM forskolin is shown in Figure 2A. After a latency period of
0.5–1 h, the enzyme activity steeply increased, and a maximum
was reached after 8 h. An incubation period of 5 h was sufficient
to obtain 76–94% of the maximum expression. To optimize assay
performance, the pEC50 value of forskolin in the respective cAMP
reporter gene assay system [29] was determined (Figure 2). As the
concentration-response curve shows an optimum (Figure 2B), only
the ascending part of the curve was considered up to a forskolin
concentration of 10 mM (Figure 2C). Interestingly, the potency of
forskolin was significantly different: pEC50 values were 6.4160.05
and 5.9560.04 in the hH4R and mH4R co-transfected cells,
respectively, and 5.5060.11 in the HEK293T-CRE-Luc cells
(Figure 2C). Forskolin concentration-dependently increased the
luciferase expression in HEK293T-SF-rH4R-His6–CRE-Luc cells,
which was inhibited by histamine (1) (Figure 3A) with pEC50
values of 6.8160.11, 6.5360.04, 6.2960.07 and 5.9160.04
(Figure 3B) at forskolin concentrations of 0.5, 1.0, 2.5 and
5 mM, respectively. Therefore, a concentration of 0.4 mM of
forskolin was used for pre-stimulating the hH4R expressing cells,
whereas 1 mM of forskolin was considered optimal for AC
stimulation in mH4R and rH4R expressing cells. With respect to
comparability of concentration-response curves of H4R ligands at
H4R orthologs, the difference between maximum forskolin
stimulation in the absence and the presence of the reference
agonist histamine (100 mM) was set to 100% (Figure 3B).
In the presence of the PDE inhibitor IBMX (50 mM) the
concentration-response curve of forskolin on HEK293T-SF-
hH4R-His6-CRE-Luc-cells was shifted to the left, resulting in an
pEC50 value of 6.8660.06 (N=3). Additionally, IBMX increased
the receptor-independent luciferase activity by about a factor of
four (data not shown). To investigate the effect of IBMX on the
Figure 8. Comparison of distal and proximal readouts.
Correlation between agonist potencies in the luciferase reporter gene
assay and the [35S]GTPcS assay at the (A) hH4R (slope: 0.9060.20;
r2 = 0.80), (B) mH4R (slope: 1.43160.23; r
2 = 0.95) and (C) rH4R (slope:
1.17160.28, r2 = 0.85).
doi:10.1371/journal.pone.0073961.g008
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concentration-response curve of the full H4R agonist histamine (1)
and the H4R inverse agonist thioperamide (20) HEK293T-hH4R-
His6-CRE-Luc cells were pre-stimulated with forskolin (0.5 mM)
alone or in combination with IBMX (50 mM) (cf. Figure 4). The
maximum responses to histamine (1) and thioperamide (20), and
thus the range of the signals, were reduced in the presence of
IBMX. Therefore, further experiments were performed in the
absence of IBMX.
Functional Activity of H4R Ligands at the Human, Mouse
and Rat H4R
A set of ligands (Figure 1), generally accepted as agonists (1–17),
neutral antagonists or inverse agonists (18–23) at the human H4R
was selected for functional investigations. The results from the
reporter gene assays performed with the H4R species orthologs are
summarized in Table 1 and compared to functional data from the
[35S]GTPcS binding assay and the literature in Table 2.
hH4R agonists (compounds 1–17). The endogenous ago-
nist histamine (1) inhibited forskolin stimulated luciferase activity
with pEC50 values of 7.77, 7.06 and 6.53 in the hH4R, mH4R and
rH4R expressing reporter cells, respectively (Table 1). The methyl-
substituted analogs of histamine (2–5) acted, with the exception of
3, as full agonists at the three H4R orthologs. Compared to the
hH4R, a trend towards decreased potency was detected at the
rodent receptors for compounds 1–5 (Figure 5A, B, C). Among the
enantiomers 2 and 3, (R)-a-methylhistamine (2) was the eutomer
at all species orthologs. Compared to immepip (6), the pyridine
analog immethridine (7) showed significantly reduced potency and
intrinsic activity at the hH4R. By contrast, immethridine (7)
exhibited almost full agonist activity at both, the mouse and rat
H4R, with similar moderate potency compared to the hH4R.
Imetit (8) exhibited almost the same potency and efficacy at the
three H4R orthologs. In contrast, clobenpropit (9) and iodophen-
propit (10), which can be considered as analogs of imetit (8) with
an increased distance between the basic moieties and a large
lipophilic group in the side chain, displayed a clear decrease in
potency and maximal response at the mouse and rat H4R
compared to the hH4R. Clobenpropit (9) was a potent full agonist
at the hH4R and only a moderate partial agonist at the mouse and
rat H4R, whereas iodophenpropit (10) acted as a partial agonist at
the hH4R and a neutral antagonist at both, the mouse and the rat
H4R. Proxyfan (11) partially activated the three H4R orthologs
with significantly lower potencies on the rodent receptors.
Whereas H4R-independent effects of 11 were negligible at
concentrations .10 mM, the structural analog ciproxifan (12)
induced a strong increase (by up to 250%) in luciferase activity at
concentrations from 1 to 100 mM in HEK293-CRE-Luc cells
devoid of H4R expression (Figure 6). Therefore, functional
activities of 12 on H4R orthologs were not determined in the
luciferase assay. The non-selective acylguanidine-type H3/4R
agonist UR-PI294 (13) fully activated the human, mouse and rat
H4R (Figure 5A, B, C), being the most potent agonist at all three
H4R orthologs (Table 1). In contrast, the selective cyanoguani-
dine-type H4R agonist UR-PI376 (14) acted as a potent full hH4R
agonist, exhibited only partial agonistic activity at the mH4R and
was devoid of agonism at the rH4R (Table 1). VUF 8430 (15) had
about the same potency at both, the mH4R and the hH4R,
whereas the potency at the rH4R was distinctly lower. At all three
H4R species orthologs, VUF8430 (15) was almost as efficacious as
histamine (a=0.96–0.98). The aminopyrimidine-type compound
ST-1006 (16) exhibited pronounced differences in the quality of
action at the H4R orthologs with nearly full agonism at the hH4R,
partial agonism at the mH4R and inverse agonism at the rH4R.
The antipsychotic drug clozapine (17) exhibited only moderate
agonistic potency at the hH4R. However, with an a value of 1.30,
clozapine was even more efficacious than histamine (1). Further-
more, clozapine (17) fully activated both, the mouse and the rat
H4R, though with low pEC50 values (Table 1).
hH4R antagonists and inverse agonists (18–23). Interest-
ingly, VUF 5681 (18), with a spacer extended by two carbon
atoms compared to the H4R agonist immepip (6), displayed no
agonistic activity at the hH4R and only partial agonism at the
mH4R. In the antagonist mode at the hH4R, VUF 5681 (18)
inhibited the histamine-induced decrease in luciferase activity with
a pKB value of 6.1660.20. JNJ 7777120 (19) behaved as neutral
antagonist at the human and mouse H4R in the luciferase reporter
gene assay with comparable pKB values of 7.8160.19 and
7.5860.13, respectively (Figure 5A, B, D). In contrast, at the
rH4R JNJ 7777120 (19) acted as a partial agonist (a=0.4960.05)
with a pEC50 value of 8.2160.10 (Figure 5C). By analogy with
ciproxifan, but much less pronounced, JNJ 7777120 (19) and
thioperamide (20) produced receptor-independent increases in
luciferase activity at concentrations $10 mM in control experi-
ments using cells devoid of H4R expression (Figure 6). The
corresponding values were therefore omitted in the construction of
concentration-response curves of 19 and 20, when studied in the
antagonist mode (shown for JNJ 7777120 (19) in Figure 5D).
Thioperamide (20) acted as an inverse agonist, achieving
comparable pEC50 values at the human and mouse H4R
(Figure 5A, B, Table 1), and revealed moderate antagonistic
acitivity at the rH4R with a pKB value of 6.8960.14. The
aminopyrimidine ST-1012 (21) acted as an inverse agonist at the
hH4R, but revealed partial agonistic activity at the mouse and the
rat H4R. The conformationally constrained aminopyrimidines A
943931 (22) and A 987306 (23) were inverse agonists at the hH4R
and neutral antagonists at the rH4R.
Discussion and Conclusions
Assay Optimization
The pEC50 value of forskolin varied among the different
transfectants probably due to different expression levels of the
CRE-controlled luciferase. The concentration-response curve
revealed a decline at forskolin concentrations higher than
10 mM. This decline of the forskolin effect became already
obvious at concentrations .3.2 mM in the presence of 50 mM of
the PDE inhibitor IBMX (data not shown), as already described
for a CRE-directed luciferase reporter gene assay in Chinese
hamster ovary cells (CHO) [37]. By analogy with a report by
Kemp et al. [38] an activation of the inducable cAMP early
repressor (ICER) may counteract the luciferase expression in
HEK293T cells. Gai-protein mediated inhibition of the cAMP
synthesis as well as the signal-to-noise ratio was lowered by
increasing concentrations of forskolin and IBMX. This was
reflected by smaller relative effects and potencies of histamine (1)
in the presence of increasing forskolin concentrations (Figure 3)
and 50 mM of IBMX (Figure 4). Thus, high forskolin concentra-
tions should be avoided and the altered potency of forskolin, when
used in combination with IBMX, must be considered in this assay.
The co-expression of a CRE-controlled luciferase reporter gene
with the human, mouse and rat H4R, respectively, in HEK293T
cells enabled the functional analysis of H4R ligands. A set of 23
imidazole and non-imidazole ligands comprising agonists, inverse
agonists and antagonists was investigated for ability to effect
forskolin stimulated luciferase activity. The obtained pEC50 values
or pKB values were compared with ligand activities from different
functional assay systems reported in literature.
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Off-target Effects
The luciferase stimulation becoming obvious at concentrations
.1 mM of JNJ7777120 (19) and thioperamide (20) in cells
expressing the H4R orthologs (cf. dashed lines in the concentra-
tion-response curves of 19 and 20 in Figure 5A-C) suggest inverse
agonism. However, the investigation of selected compounds on
HEK293T-CRE-Luc cells lacking the H4R (cf. Figure 6) revealed
H4R-independent increase in luciferase activity. This effect was
most prominent in case of ciproxifan (12), but also pronounced for
19 and 20. Therefore, off-target effects should be taken into
account to avoid misinterpretation of biological responses to such
compounds at concentrations $10 mM.
Activities at the Human H4 Receptor
Except for ST-1006 (16) [39], all determined H4R ligand
activities at the hH4R were in agreement with results reported in
literature [20,23,39–42]. However, a tendency toward elevated
intrinsic activities was observed. Contrary to partial agonistic
activity of immepip (6) and clobenpropit (9) in the [35S]GTPcS
binding assay on membrane preparations of H4R expressing Sf9
cells (a=0.81and 0.45, respectively) (Table 2), full agonism at the
hH4R was determined in the luciferase assay. Iodophenpropit (10),
described as a neutral antagonist [40], exerted strong partial
agonistic activity at the hH4R in the present study. Partial
agonistic activity was also determined for iodophenpropit (10) in a
Ca2+ mobilization assay in HEK293 cells, co-transfected with the
hH4R and the chimeric G-protein Gqi5 [5]. ST-1006 (16) had low
intrinsic activity in the [32P]GTPase and [35S]GTPcS binding
assay at the hH4R [39], but was an almost full agonist in the
luciferase assay. The increased intrinsic activity was accompanied
with a decrease in potency of about one order of magnitude. In
case of clozapine (17), the maximal agonistic response surpassed
that of histamine by 30%. In control experiments on HEK293T-
CRE-Luc cells devoid of the H4R, clozapine (17) at concentrations
as high as 100 mM caused an increase in CRE-activity by up to
17% (data not shown). The effect of clozapine on hH4R expressing
cells was antagonized by JNJ 7777120 in a concentration-
dependent manner, indicating that the (super)agonistic effect was
receptor mediated (Figure 7). Using histamine or clozapine as H4R
agonists revealed approximately the same pA2 value for JNJ
7777120 (pA2 values: 8.39 and 8.17). However, compared to the
concentration response curve of histamine in the presence of JNJ
7777120 (Figure 7A), the extent of rightward shift was smaller in
case of clozapine (Figure 7B), resulting in different slopes (0.83
compared to 0.45) of the corresponding Schild plots (Figure 7C).
This may be taken as a hint that histamine and clozapine activate
the H4R not exactly in the same way. However, due to the
pleiotropic character of clozapine (17), effects mediated by targets
other than the H4R must be taken into account. Most probably,
increased intrinsic activities in the luciferase assay compared to
more proximal readouts are caused by amplifications in signaling
downstream from G-protein activation [30,37]. For instance, in
functional assays on Sf9 cell membranes, ST-1006 (16) [39] and
clozapine (17) [43] showed only partial agonism (Table 2).
The constitutive activity of the hH4R, obvious from inverse
agonism of thioperamide (20), was rather low compared to
functional assays on Sf9 cell membranes [23,34]. In accordance
with reported data ST-1012 (21) acted as an inverse hH4R agonist
in the [35S]GTPcS assay [39], and JNJ 7777120 (19) behaved as a
neutral hH4R antagonist [18,40]. Inverse agonism was also found
for A 943931 (22) and A 987306 (23) in the luciferase (Table 1)
and the GTPcS assay (Table 2), whereas neutral antagonism was
observed in Ca2+ (FLIPR) assays [44,45].
Activities at Rodent H4 Receptors
Comparing the results from the luciferase assay on mouse and
rat H4R with data from other functional assays revealed marked
differences. The potencies of histamine (1), 5(4)-methylhistamine
(5), immepip (6), UR-PI294 (13), VUF 8430 (15) and clozapine
(17) were significantly higher compared to the [32P]GTPase [23]
and [35S]GTPcS binding assay (Table 2). By contrast, the agonist
potencies of histamine (1), (R)-a-methylhistamine (2), Na-methyl-
histamine (4) and imetit (8) were consistent or lower compared to
results from a Ca2+ assay using HEK293 cells, co-expressing the
mouse or the rat H4R with Gaqi5 [2,46]. For example, in the
luciferase assay the pEC50 values of histamine (1) were in good
agreement with results from the Ca2+ assay at the mouse and rat
H4R (7.23 and 6.49, respectively) [46], but distinctly higher
compared to pEC50 values from the [
32P]GTPase assay (5.81 and
5.23, respectively) [23]. UR-PI294 (13) achieved pEC50 values .8
at the hH4R, mH4R and rH4R in the luciferase assay, whereas the
[32P]GTPase assay revealed dramatic differences in pEC50 values
(8.52, 6.50 and 4.64, respectively) [23]. The potency of imetit (8)
was lower compared to the Ca2+ assay in HEK293 cells (pEC50
values: 7.4 and 7.2 vs. 8.1 at both receptors) [20]. Whereas being
full agonists in the luciferase assay, (R)-a-methylhistamine (2), Na-
methylhistamine (4) and imetit (8) only reached 75–80% of the
maximal Ca2+ response at the mH4R and 30–50% at the rH4R
[20].
The pKB values of neutral antagonists, such as iodophenpropit
(10) at the mouse and rat H4R as well as thioperamide (20) and
UR-PI376 (14) at the rH4R were comparable to those determined
in the [35S]GTPcS binding assay (Table 2). Mouse and rat H4R-
mediated inhibition of forskolin-stimulated luciferase activity in
HEK293T-CRE-Luc cells resulted in higher potencies compared
to functional assays using Ga-protein activation as readout. This
suggests that signal amplification or concomitant activation of
different signaling pathways potentiates the inhibition of the
luciferase activity. For example, the cAMP pathway may be
modulated by a cross-talk with Ca2+ signaling elicited by activation
of phospholipase C (PLC) [47]. Ca2+ is an inhibitor of (forskolin)
stimulated and Ca2+ sensitive adenylate cyclases type V/VI [48–
50], which are endogenously expressed in HEK293T cells [51]
and interact with the Gai protein [52]. Furthermore, the relevance
of this crosstalk with regard to the cAMP signaling pathway of G-
protein coupled receptors (GPCRs) was demonstrated by the
inhibitory effect of the activated Gaq coupled histamine H1R on
the cAMP level in U373 MG cells [53] and, more importantly, by
a crosstalk between the Gai coupled M2 mACh receptor and the
Gaq coupled M3 mACh receptor. In the latter case the inhibition
of forskolin-stimulated cyclic AMP accumulation was facilitated at
low agonist concentrations [54]. Further studies on the influence of
Ca2+ are needed to clarify, whether only the rodent H4Rs are
concerned, since agonist potencies at the hH4R were consistent
with data from the [32P]GTPase and [35S]GTPcS binding assay
(Table 2). Very recently, investigations on human esosinophils
revealed a lower Ca2+ response to stimulation by histamine (1) and
UR-PI376 (14) compared to the chemokine eotaxin via the CCR3
receptor [55]. This may be interpreted as a hint to minor
contribution of Ca2+ signaling to the overall H4R mediated
response, at least in native human cells. The presence of a range of
alternative signaling pathways for the H4R in living cells was
underlined recently by the Ga independent ß-arrestin recruitment
of several H4R ligands [26,27].
The results for the standard antagonist JNJ 7777120 (19) at the
mouse and rat H4R compared with data reported for other
functional assays revealed discrepancies, too. In the luciferase
assay JNJ 7777120 (19) acted as a neutral antagonist at the mH4R,
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but as a potent partial agonist at the rH4R. Antagonistic activity at
both receptors was found in a CRE-driven b-galactosidase assay in
SK-N-MC cells [18] and in a Ca2+ assay in HEK293 cells [46],
whereas partial agonistic activity was determined at the mouse and
rat receptor in the [32P]GTPase [23] and [35S]GTPcS binding
assay (Table 2). The pKB value at the mH4R in the luciferase assay
is consistent with the pKB value in the Ca
2+ assay [46], whereas
the agonistic potency at the rH4R is about two orders of
magnitude higher compared to the [32P]GTPase assay [23].
Discrepancies between the H4R orthologs in the different assay
systems may result from differential equilibria between the active
and inactive states of the H4R in the different assay systems as
described recently [56]. In the luciferase assay, the constitutive
activity, reflected by the inverse agonism of compounds 20–23,
was considerably higher for the mH4R than for the rH4R. At the
latter JNJ 7777120 shifted the equilibrium toward the active state,
becoming obvious as agonistic activity. Inversely, ST1006 (16), a
potent agonist a human and mouse H4R, showed considerable
inverse agonism at the rH4R. Thus, the outcome of studies in
translational animal models cannot be unequivocally predicted by
in vitro experiments, but such data may help to interprete
conflicting results such as the pro-inflammatory effect of JNJ
7777120 (19) in a rat conjunctivitis model [17].
In case of agonism at the human H4R, the data correlate very
well with data provided by more proximal readouts such as
GTPase activity or GTPcS binding (Table 1, Table 2, Figure 8A).
This also holds for the rank order of agonists at the mouse and rat
H4R (Table 1, Table 2, Figure 8B,C), however, the potencies are
up to 100-fold higher in the luciferase assay.
Conclusions
The reporter gene (luciferase) assay in HEK293T cells allows
for the quantification of agonistic, inverse agonistic and antago-
nistic activity at the H4R species orthologs in a highly sensitive and
reliable manner. In view of significantly increased potencies and
efficacies of agonists, especially at the rodent H4R orthologs,
obviously, there is a positive effect on the readout by activation/
amplification of or cross-talk between different signaling pathways
in the luciferase reporter gene assay compared to more proximal
functional assays on Sf9 cell membranes. It has now become clear
that unequivocal characterization of H4R ligands as agonists,
antagonists or inverse agonists in assays using a single readout is
impossible. Thus, ligands have to be examined in multiple assays.
But at present, it seems impossible to predict the value of the
in vitro data with respect to translational animal studies and their
clinical relevance.
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